WO2017029261A1 - Préparation combinée contenant de la finérénone et un inhibiteur de nep (sacubitril) - Google Patents

Préparation combinée contenant de la finérénone et un inhibiteur de nep (sacubitril) Download PDF

Info

Publication number
WO2017029261A1
WO2017029261A1 PCT/EP2016/069336 EP2016069336W WO2017029261A1 WO 2017029261 A1 WO2017029261 A1 WO 2017029261A1 EP 2016069336 W EP2016069336 W EP 2016069336W WO 2017029261 A1 WO2017029261 A1 WO 2017029261A1
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
treatment
prophylaxis
combination preparation
preparation according
Prior art date
Application number
PCT/EP2016/069336
Other languages
German (de)
English (en)
Inventor
Peter Kolkhof
Peter Sandner
Christina NOWAK
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Publication of WO2017029261A1 publication Critical patent/WO2017029261A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne l'utilisation de l'agoniste du récepteur minéralocorticoïde finérénone en combinaison avec un inhibiteur de l'endopeptidase neutre (NEP), pour traiter et/ou prévenir des troubles du système cardiovasculaire, des troubles rénaux, des troubles pulmonaires et pour traiter et/ou prévenir des troubles fibrotiques.
PCT/EP2016/069336 2015-08-19 2016-08-15 Préparation combinée contenant de la finérénone et un inhibiteur de nep (sacubitril) WO2017029261A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15181581 2015-08-19
EP15181581.8 2015-08-19

Publications (1)

Publication Number Publication Date
WO2017029261A1 true WO2017029261A1 (fr) 2017-02-23

Family

ID=53879434

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2016/069336 WO2017029261A1 (fr) 2015-08-19 2016-08-15 Préparation combinée contenant de la finérénone et un inhibiteur de nep (sacubitril)

Country Status (1)

Country Link
WO (1) WO2017029261A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3566704A1 (fr) * 2018-05-11 2019-11-13 Bayer Aktiengesellschaft Utilisation d'antagonistes des récepteurs minéralocorticoïdes non stéroïdiens seuls ou en combinaison, pour le traitement de maladies musculaires ou neuromusculaires

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217996A (en) * 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
US20040192584A1 (en) * 2003-03-18 2004-09-30 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a neutral endopeptidase inhibitor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217996A (en) * 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
US20040192584A1 (en) * 2003-03-18 2004-09-30 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a neutral endopeptidase inhibitor

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ADIS MEDICAL WRITERS: "Consider mineralocorticoid receptor antagonists as add-on therapy in treatment-resistant hypertension", DRUGS AND THERAPY PERSPECTIVES, ADIS INTERNATIONAL, AUCKLAND, NZ, vol. 31, no. 10, 21 July 2015 (2015-07-21), pages 345 - 349, XP009191544, ISSN: 1172-0360, DOI: 10.1007/S40267-015-0229-6 *
FRANCESCO ORSO ET AL: "Newest additions to heart failure treatment", EXPERT OPINION ON PHARMACOTHERAPY, vol. 15, no. 13, 1 September 2014 (2014-09-01), LONDON, UK, pages 1849 - 1861, XP055306645, ISSN: 1465-6566, DOI: 10.1517/14656566.2014.934812 *
JOHN J.V. MCMURRAY ET AL: "Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure", NEW ENGLAND JOURNAL OF MEDICINE, vol. 371, no. 11, 11 September 2014 (2014-09-11), pages 993 - 1004, XP055175908, ISSN: 0028-4793, DOI: 10.1056/NEJMoa1409077 *
LARS BÄRFACKER ET AL: "Discovery of BAY 94-8862: A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal Diseases", CHEMMEDCHEM, vol. 7, no. 8, 12 August 2012 (2012-08-12), pages 1385 - 1403, XP055213619, ISSN: 1860-7179, DOI: 10.1002/cmdc.201200081 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3566704A1 (fr) * 2018-05-11 2019-11-13 Bayer Aktiengesellschaft Utilisation d'antagonistes des récepteurs minéralocorticoïdes non stéroïdiens seuls ou en combinaison, pour le traitement de maladies musculaires ou neuromusculaires
WO2019215317A1 (fr) * 2018-05-11 2019-11-14 Bayer Aktiengesellschaft Utilisation d'antagonistes non stéroïdiens du récepteur des minéralocorticoïdes seuls ou en combinaison pour le traitement de maladies musculaires ou neuromusculaires
US11439628B2 (en) 2018-05-11 2022-09-13 Bayer Aktiengesellschaft Use of non-steroidal mineralocorticoid receptor antagonists alone or in combination for the treatment of muscular or neuromuscular diseases

Similar Documents

Publication Publication Date Title
US11331308B2 (en) Combination containing sGC activators and mineralocorticoid receptor antagonists
EP3325013B1 (fr) Stimulateurs / activateurs de guanylate cyclase soluble en combinaison avec un inhibiteur de l'endopeptidase neutrale (nep) et/ou un antagonist d'angiotensin ii et son utilisation
EP3525779A1 (fr) Combinaison contenant des stimulateurs gcs et des antagonistes du récepteur des minéralocorticoïdes
CN104159899A (zh) 取代的三嗪衍生物及其作为可溶性鸟苷酸环化酶激发物的用途
WO2017029261A1 (fr) Préparation combinée contenant de la finérénone et un inhibiteur de nep (sacubitril)
US20110178137A1 (en) Diaryl urea for treating heart failure
WO2017029258A1 (fr) Préparation combinée comprenant de la finérénone et du valsartan
WO2018153899A1 (fr) Agonistes partiels sélectifs du récepteur a1 de l'adénosine en combinaison avec des stimulateurs et/ou activateurs de la guanylate cyclase soluble (sgc)
DE102017008472A1 (de) Kombination enthaltend PDE5 Inhibitoren und Mineralocorticoid-Rezeptor-Antagonisten
WO2018153898A1 (fr) Agonistes partiels sélectifs du récepteur a1 de l'adénosine en combinaison avec des antagonistes du récepteur des minéralocorticoïdes
WO2018153900A1 (fr) Agonistes partiels sélectifs du récepteur a1 de l'adénosine en combinaison avec des inhibiteurs de sglt-2
WO2018153895A1 (fr) Agonistes partiels sélectifs du récepteur a1 de l'adénosine en combinaison avec un inhibiteur de l'endopeptidase neutre et/ou un antagoniste du récepteur de l'angiotensine ii
WO2018153897A1 (fr) Agonistes partiels sélectifs du récepteur a1 de l'adénosine en combinaison avec des inhibiteurs des canaux hcn
TW202412753A (zh) 用於治療女性心臟衰竭合併保留射出分率的可溶性鳥苷酸環化酶活化劑
WO2023237577A1 (fr) Activateurs de guanylate cyclase soluble destinés à être utilisés dans le traitement de l'insuffisance cardiaque à fraction d'éjection préservée chez les femmes
DE102012200351A1 (de) Substituierte annellierte Pyrimidine und ihre Verwendung

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16750870

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16750870

Country of ref document: EP

Kind code of ref document: A1